The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1494
ISSUE1494
May 9, 2016
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
May 9, 2016 (Issue: 1494)
The FDA has approved ixekizumab (Taltz – Lilly), an
injectable humanized interleukin (IL)-17A antagonist,
for treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy
or phototherapy. Ixekizumab is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.